"Lovastatin" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.
Descriptor ID |
D008148
|
MeSH Number(s) |
D02.455.426.559.847.638.400 D04.615.638.400
|
Concept/Terms |
Lovastatin- Lovastatin
- Mevinolin
- Monacolin K
- 6-Methylcompactin
- 6 Methylcompactin
|
Below are MeSH descriptors whose meaning is more general than "Lovastatin".
Below are MeSH descriptors whose meaning is more specific than "Lovastatin".
This graph shows the total number of publications written about "Lovastatin" by people in this website by year, and whether "Lovastatin" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2008 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Lovastatin" by people in Profiles.
-
Wang A, Stefanick ML, Kapphahn K, Hedlin H, Desai M, Manson JA, Strickler H, Martin L, Wactawski-Wende J, Simon M, Tang JY. Relation of statin use with non-melanoma skin cancer: prospective results from the Women's Health Initiative. Br J Cancer. 2016 Feb 02; 114(3):314-20.
-
Tilahun ME, Kwan A, Natarajan K, Quinn M, Tilahun AY, Xie C, Margulies DH, Osborne BA, Goldsby RA, Rajagopalan G. Chimeric anti-staphylococcal enterotoxin B antibodies and lovastatin act synergistically to provide in vivo protection against lethal doses of SEB. PLoS One. 2011; 6(11):e27203.
-
Jameson JM, Cruz J, Costanzo A, Terajima M, Ennis FA. A role for the mevalonate pathway in the induction of subtype cross-reactive immunity to influenza A virus by human gammadelta T lymphocytes. Cell Immunol. 2010; 264(1):71-7.
-
Xiao H, Yang CS. Combination regimen with statins and NSAIDs: a promising strategy for cancer chemoprevention. Int J Cancer. 2008 Sep 01; 123(5):983-90.
-
Aarons CB, Cohen PA, Gower A, Reed KL, Leeman SE, Stucchi AF, Becker JM. Statins (HMG-CoA reductase inhibitors) decrease postoperative adhesions by increasing peritoneal fibrinolytic activity. Ann Surg. 2007 Feb; 245(2):176-84.
-
Guharoy R. Risks of a nonprescription lovastatin. Am J Health Syst Pharm. 2005 Jul 15; 62(14):1444-5.
-
Erl W, Hristov M, Neureuter M, Yan ZQ, Hansson GK, Weber PC. HMG-CoA reductase inhibitors induce apoptosis in neointima-derived vascular smooth muscle cells. Atherosclerosis. 2003 Aug; 169(2):251-8.
-
Hrboticky N, Draude G, Hapfelmeier G, Lorenz R, Weber PC. Lovastatin decreases the receptor-mediated degradation of acetylated and oxidized LDLs in human blood monocytes during the early stage of differentiation into macrophages. Arterioscler Thromb Vasc Biol. 1999 May; 19(5):1267-75.
-
Hrboticky N, Becker A, Kruse HJ, Weber PC. Increased cellular triglyceride levels in human monocytic and rat smooth muscle cells after lovastatin. Biochim Biophys Acta. 1997 Nov 30; 1349(3):211-21.
-
Weber C, Erl W, Weber KS, Weber PC. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 1997 Nov 01; 30(5):1212-7.